A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

June 13, 2024

Study Completion Date

February 28, 2027

Conditions
Prostate Cancer
Interventions
RADIATION

Adaptive radiotherapy according to UPRATE protocol

According to previously reported STAMPEDE trial (Parker et al.), patients will be treated with 6 weekly fractions of 6 Gy. According to local protocol the target will consist of prostate and entire seminal vesicles. Additional CT-scans will be made prior to and directly following each fraction. For more details, see study description

Trial Locations (1)

3015

Erasmus Medical Centre, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER